Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1182–1184. doi: 10.1128/aac.39.5.1182

Concentration of pefloxacin in feces during infection prophylaxis in neutropenic patients.

J J van de Leur 1, E J Vollaard 1, A J Janssen 1, A S Dofferhoff 1
PMCID: PMC162706  PMID: 7625811

Abstract

Pefloxacin (400 mg twice daily) was administered orally for infection prophylaxis in neutropenic patients. Diffusible fecal pefloxacin concentration was determined by bioassay during 24 neutropenic periods. The median diffusible fecal pefloxacin concentration was 187 micrograms/g. This concentration was comparable with those found in volunteers following oral and intravenous administration of pefloxacin (400 mg twice daily) (median of 171 and 155 micrograms/g, respectively). From this study, it is concluded that pefloxacin administered orally results in a predictable high diffusible fecal concentration which leads to effective elimination of susceptible aerobic gram-negative bacilli from the colonic flora.

Full Text

The Full Text of this article is available as a PDF (156.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arning M., Wolf H. H., Aul C., Heyll A., Scharf R. E., Scheider W. Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin. J Antimicrob Chemother. 1990 Nov;26 (Suppl 500):137–142. doi: 10.1093/jac/26.suppl_d.137. [DOI] [PubMed] [Google Scholar]
  2. Bow E. J., Louie T. J. Emerging role of quinolones in the prevention of gram-negative bacteremia in neutropenic cancer patients and in the treatment of enteric infections. Clin Invest Med. 1989 Feb;12(1):61–68. [PubMed] [Google Scholar]
  3. Clasener H. A., Vollaard E. J., van Saene H. K. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis. 1987 Mar-Apr;9(2):295–328. doi: 10.1093/clinids/9.2.295. [DOI] [PubMed] [Google Scholar]
  4. Donnelly J. P., Maschmeyer G., Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer. 1992;28A(4-5):873–878. doi: 10.1016/0959-8049(92)90138-r. [DOI] [PubMed] [Google Scholar]
  5. Donnelly J. P. Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. J Antimicrob Chemother. 1993 Jun;31(6):813–829. doi: 10.1093/jac/31.6.813. [DOI] [PubMed] [Google Scholar]
  6. Farmer J. J., 3rd, Davis B. R., Hickman-Brenner F. W., McWhorter A., Huntley-Carter G. P., Asbury M. A., Riddle C., Wathen-Grady H. G., Elias C., Fanning G. R. Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol. 1985 Jan;21(1):46–76. doi: 10.1128/jcm.21.1.46-76.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gonzalez J. P., Henwood J. M. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1989 May;37(5):628–668. doi: 10.2165/00003495-198937050-00003. [DOI] [PubMed] [Google Scholar]
  8. Karp J. E., Merz W. G., Hendricksen C., Laughon B., Redden T., Bamberger B. J., Bartlett J. G., Saral R., Burke P. J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987 Jan;106(1):1–7. doi: 10.7326/0003-4819-106-1-1. [DOI] [PubMed] [Google Scholar]
  9. Liang R. H., Yung R. W., Chan T. K., Chau P. Y., Lam W. K., So S. Y., Todd D. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990 Feb;34(2):215–218. doi: 10.1128/aac.34.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Menichetti F., Felicini R., Bucaneve G., Aversa F., Greco M., Pasquarella C., Moretti M. V., Del Favero A., Martelli M. F. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1989 Sep;4(5):489–492. [PubMed] [Google Scholar]
  11. Rohwedder R., Bergan T., Thorsteinsson S. B., Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy. 1990;36(2):77–84. doi: 10.1159/000238751. [DOI] [PubMed] [Google Scholar]
  12. Rubinstein E., St Julien L., Ramon J., Dautrey S., Farinotti R., Huneau J. F., Carbon C. The intestinal elimination of ciprofloxacin in the rat. J Infect Dis. 1994 Jan;169(1):218–221. doi: 10.1093/infdis/169.1.218. [DOI] [PubMed] [Google Scholar]
  13. Vollaard E. J., Clasener H. A. Colonization resistance. Antimicrob Agents Chemother. 1994 Mar;38(3):409–414. doi: 10.1128/aac.38.3.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Vollaard E. J., Clasener H. A., Janssen A. J. Decontamination of the bowel by intravenous administration of pefloxacin. J Antimicrob Chemother. 1990 Dec;26(6):847–852. doi: 10.1093/jac/26.6.847. [DOI] [PubMed] [Google Scholar]
  15. Vollaard E. J., Clasener H. A., Janssen A. J. Influence of pefloxacin on microbial colonization resistance in healthy volunteers. Eur J Clin Microbiol Infect Dis. 1992 Mar;11(3):257–260. doi: 10.1007/BF02098093. [DOI] [PubMed] [Google Scholar]
  16. Warren R. E., Wimperis J. Z., Baglin T. P., Constantine C. E., Marcus R. Prevention of infection by ciprofloxacin in neutropenia. J Antimicrob Chemother. 1990 Dec;26 (Suppl F):109–123. doi: 10.1093/jac/26.suppl_f.109. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES